Structured evidence table for Chia Lipid Profile Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Chia Lipid Profile Randomized Trial | Conclusions In real-world clinical practice, bempedoic acid use is associated with a higher incidence of laboratory-defined hyperuricemia compared with ezetimibe, but this increase does not translate into greater use of anti-gout medications. | 4 | Su PH (2026) | Hyperuricemia risk in bempedoic acid-treated hyperlipidemic patients. |
| Chia Lipid Profile Randomized Trial | Background Bempedoic acid is an oral cholesterol-lowering medication used to reduce low-density lipoprotein cholesterol (LDL-C), particularly in patients who require additional lipid lowering. | 4 | Su PH (2026) | Hyperuricemia risk in bempedoic acid-treated hyperlipidemic patients. |
| Chia Lipid Profile Randomized Trial | Clinical trials have shown that bempedoic acid increases serum uric acid levels, but the implications of this effect in real-world clinical practice, including the need for anti-gout treatment, are not well defined. | 4 | Su PH (2026) | Hyperuricemia risk in bempedoic acid-treated hyperlipidemic patients. |
Source documents